Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cerenis Therapeutics has commenced a double-blind, randomized, placebo-controlled, safety and efficacy Phase 2 CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis Regression?) study to evaluate CER-001 in patients suffering from acute coronary syndrome (ACS).
Subscribe to our email newsletter
The study expects to examine CER-001’s ability to regress coronary atherosclerotic plaque as measured by intravascular ultrasound (IVUS).
Cerenis is expecting to involve around 500 patients at 50 centers in the US, Canada and Europe.
Principal investigator of the study Jean-Claude Tardif said thisis the largest IVUS study conducted with a pre-beta HDL mimetic, and represents a potential new treatment paradigm to reduce the burden of atherosclerosis.
Cerenis CEO Jean-Louis Dasseux said following the excellent safety and tolerability Phase I results with CER-001, this trial will evaluate the efficacy in ACS patients.
"The potential of HDL therapy is well recognized and CER-001, as a first in class pre-beta HDL mimetic, could have great therapeutic value to patients with ACS," Dasseux said.